[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Moore KH, Barry P, Burn J, Falk G: Adenocarcinoma of the rat esophagus in the presence of a proton pump inhibitor: a pilot study. Dis Esophagus; 2001;14(1):17-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the rat esophagus in the presence of a proton pump inhibitor: a pilot study.
  • This study examines the effects of a proton pump inhibitor on a rat model of duodenogastric reflux.
  • Rats were examined at death for macroscopic tumor, dysplasia, adenocystic changes, papillomatosis, and adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. OMEPRAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11422300.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proton Pump Inhibitors; 0 / Proton Pumps; KG60484QX9 / Omeprazole
  •  go-up   go-down


2. Mercalli A, Sordi V, Formicola R, Dandrea M, Beghelli S, Scarpa A, Di Carlo V, Reni M, Piemonti L: A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer. Br J Cancer; 2007 May 7;96(9):1358-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gemcitabine (GEM)-based chemotherapy is regarded as the standard treatment of pancreatic adenocarcinoma, but yields a very limited disease control.
  • MIA PaCa2, CFPAC-1 and Capan-1 pancreatic cancer cell lines were treated with GEM, fluouracil (5-FU), docetaxel (DCT), oxaliplatin (OXP), irinotecan (CPT-11), pemetrexed (PMX) and raltitrexed (RTX) as single agent.
  • Pemetrexed, inducing apoptosis with IC50s under the Cmax in the three lines tested, appeared the most effective drug as single agent.
  • Based on these results, schedule- and concentration-dependent drug interactions (assessed using the combination index) of PMX/GEM, PMX/DCT and PMX-CPT-11 were evaluated.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Camptothecin / analogs & derivatives. Glutamates / pharmacology. Guanine / analogs & derivatives. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Cycle / drug effects. Cell Line, Tumor. Drug Administration Schedule. Female. Humans. Mice. Mice, Nude. Pemetrexed. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. GUANINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2002 Jul 15;87(2):161-7 [12107836.001]
  • [Cites] J Clin Oncol. 2002 Jul 15;20(14):3130-6 [12118027.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3270-5 [12149301.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1185-91 [12181240.001]
  • [Cites] Cancer. 2002 Aug 15;95(4 Suppl):928-32 [12209673.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 20):9-16 [12577228.001]
  • [Cites] Br J Cancer. 2003 Apr 22;88(8):1180-4 [12698181.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3296-302 [12947065.001]
  • [Cites] World J Surg. 2003 Oct;27(10):1075-84 [12925907.001]
  • [Cites] Expert Rev Anticancer Ther. 2003 Oct;3(5):587-93 [14599083.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1430-8 [15084616.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):2936-43 [15131028.001]
  • [Cites] Cancer. 2004 Jul 1;101(1):133-8 [15221998.001]
  • [Cites] J Clin Oncol. 2004 Sep 15;22(18):3776-83 [15365074.001]
  • [Cites] Cancer. 1990 May 15;65(10):2207-12 [2189551.001]
  • [Cites] J Clin Oncol. 1991 Mar;9(3):491-8 [1999720.001]
  • [Cites] J Clin Oncol. 1993 May;11(5):950-8 [8098059.001]
  • [Cites] Cancer Treat Rev. 1993 Oct;19(4):351-86 [8106152.001]
  • [Cites] J Clin Oncol. 1993 Nov;11(11):2194-204 [8229134.001]
  • [Cites] J Natl Cancer Inst. 1994 Oct 19;86(20):1517-24 [7932806.001]
  • [Cites] Ann Oncol. 1995 Feb;6(2):129-32 [7786820.001]
  • [Cites] Eur J Cancer. 1995 Jun;31A(6):882-7 [7646915.001]
  • [Cites] Semin Oncol. 1996 Apr;23(2):220-8 [8623058.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1495-503 [8622063.001]
  • [Cites] Am J Health Syst Pharm. 1997 Jan 15;54(2):162-70; quiz 197-8 [9117804.001]
  • [Cites] Cancer Res. 1997 Mar 15;57(6):1116-23 [9067281.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;39(6):521-31 [9118464.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Clin Pharmacokinet. 1997 Oct;33(4):245-59 [9342501.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1470-8 [9552054.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;42(1):71-6 [9619761.001]
  • [Cites] Br J Cancer. 1998 Nov;78(9):1188-93 [9820178.001]
  • [Cites] Biochem Pharmacol. 1998 Nov 15;56(10):1315-22 [9825730.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1261-8 [10189130.001]
  • [Cites] Br J Cancer. 1999 Jun;80(7):981-90 [10362105.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3671-6 [10446980.001]
  • [Cites] Eur J Cancer. 1999 May;35(5):796-807 [10505042.001]
  • [Cites] Oncology. 2004;67(2):93-7 [15539911.001]
  • [Cites] Cancer Invest. 2004;22(5):688-96 [15581049.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Jun;55(6):522-30 [15754203.001]
  • [Cites] Lancet Oncol. 2005 Jun;6(6):369-76 [15925814.001]
  • [Cites] Am J Clin Oncol. 2005 Aug;28(4):345-50 [16062075.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1639-45 [16087696.001]
  • [Cites] Semin Oncol. 1999 Apr;26(2 Suppl 6):48-54 [10598555.001]
  • [Cites] Semin Oncol. 1999 Apr;26(2 Suppl 6):82-8 [10598560.001]
  • [Cites] Semin Oncol. 1999 Apr;26(2 Suppl 6):99-104 [10598563.001]
  • [Cites] Ann Oncol. 2000 Jan;11(1):101-3 [10690396.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1748-57 [10764436.001]
  • [Cites] Pharmacol Ther. 2000 Aug-Sep;87(2-3):227-53 [11008002.001]
  • [Cites] Anticancer Drugs. 2000 Sep;11(8):635-8 [11081455.001]
  • [Cites] Drugs. 2000 Oct;60(4):895-924 [11085200.001]
  • [Cites] Br J Cancer. 2001 Mar 2;84(5):600-3 [11237378.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6D):5209-12 [11326696.001]
  • [Cites] Curr Opin Oncol. 2001 Jul;13(4):275-86 [11429486.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3447-55 [11481349.001]
  • [Cites] Cancer Chemother Pharmacol. 2001 Aug;48(2):141-4 [11561780.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):233-9 [11801564.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):140-5 [12007952.001]
  • [Cites] Br J Cancer. 2006 Mar 27;94(6):785-91 [16508631.001]
  • [Cites] Br J Cancer. 2006 Sep 4;95(5):587-92 [16909140.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):532-9 [17255275.001]
  • [Cites] Ann Oncol. 2007 Mar;18(3):498-503 [17158774.001]
  • [Cites] Cancer Res. 1993 Mar 1;53(5):1037-42 [8094996.001]
  • (PMID = 17426706.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ PMC2360188
  •  go-up   go-down


3. Reni M, Cereda S, Bonetto E, Viganò MG, Passoni P, Zerbi A, Balzano G, Nicoletti R, Staudacher C, Di Carlo V: Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol; 2007 Feb;59(3):361-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma.
  • BACKGROUND: PEFG regimen (cisplatin and epirubicin 40 mg/m2 day 1, gemcitabine 600 mg/m2 days 1 and 8, 5-fluorouracil (FU) 200 mg/m2/day continuous infusion) significantly improved the outcome of patients with advanced pancreatic adenocarcinoma (PA) with respect to standard gemcitabine in a previous phase III trial.
  • MATERIAL AND METHODS: Dose-intense PEFG was administered to chemotherapy-naive patients with stages III-IV PA, < 75 years, performance status (PS) > 50, till progressive disease or for a maximum of 6 months.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Dose-Response Relationship, Drug. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16807732.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


Advertisement
4. Reni M: Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing? World J Gastroenterol; 2010 Oct 21;16(39):4883-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This paper discusses the rationale for phase III testing of neoadjuvant therapy in patients affected by resectable pancreatic adenocarcinoma.
  • Conflicting data on the role of adjuvant chemoradiation have been reported, while adjuvant single-agent chemotherapy significantly improved overall survival (OS) when compared to surgery alone.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials, Phase III as Topic. Pancreatectomy. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Clinical Trials, Phase II as Topic. Evidence-Based Medicine. Humans. Neoadjuvant Therapy. Radiotherapy, Adjuvant. Randomized Controlled Trials as Topic. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 2007 Feb;59(3):361-7 [16807732.001]
  • [Cites] Pancreatology. 2006;6(5):454-63 [16847383.001]
  • [Cites] JAMA. 2007 Jan 17;297(3):267-77 [17227978.001]
  • [Cites] Anticancer Drugs. 2007 Mar;18(3):263-71 [17264757.001]
  • [Cites] Ann Surg Oncol. 2007 Jul;14(7):2088-96 [17453298.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Jan;61(1):167-75 [17440727.001]
  • [Cites] JAMA. 2008 Mar 5;299(9):1019-26 [18319412.001]
  • [Cites] J Chemother. 2008 Feb;20(1):119-25 [18343754.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3487-95 [18640929.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3496-502 [18640930.001]
  • [Cites] Eur J Surg Oncol. 2009 Jun;35(6):600-4 [19131205.001]
  • [Cites] Cancer. 2009 Jun 15;115(12):2630-9 [19353729.001]
  • [Cites] J Clin Oncol. 2009 Aug 10;27(23):3778-85 [19581537.001]
  • [Cites] Anticancer Drugs. 2010 Apr;21(4):459-64 [20110805.001]
  • [Cites] J Clin Oncol. 2010 Apr 1;28(10):1645-51 [20194854.001]
  • [Cites] Cancer Invest. 2007;25(7):594-8 [17852117.001]
  • [Cites] Cancer Chemother Pharmacol. 2012 Jan;69(1):115-23 [21626049.001]
  • [Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]
  • [Cites] Ann Oncol. 2000 Nov;11(11):1399-403 [11142479.001]
  • [Cites] J Clin Oncol. 2001 May 15;19(10):2679-86 [11352960.001]
  • [Cites] Ann Surg Oncol. 2001 Dec;8(10):758-65 [11776488.001]
  • [Cites] Cancer. 2002 Feb 15;94(4):902-10 [11920457.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2537-44 [12011133.001]
  • [Cites] J Clin Oncol. 2002 Jul 15;20(14):3130-6 [12118027.001]
  • [Cites] Am J Surg. 2003 May;185(5):476-80 [12727570.001]
  • [Cites] Ann Oncol. 2004 Mar;15(3):474-7 [14998851.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):437-43 [15380577.001]
  • [Cites] Arch Surg. 1985 Aug;120(8):899-903 [4015380.001]
  • [Cites] Stat Med. 1986 Sep-Oct;5(5):441-7 [3786998.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2124-33 [8374871.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):928-37 [9060530.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):317-23 [9440759.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1228-36 [15718320.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3509-16 [15908661.001]
  • [Cites] Lancet Oncol. 2005 Jun;6(6):369-76 [15925814.001]
  • [Cites] Oncology. 2005;68(2-3):239-45 [16015040.001]
  • [Cites] Ann Oncol. 2007 Jan;18(1):82-7 [17030546.001]
  • (PMID = 20954273.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2957595
  •  go-up   go-down


5. Reni M, Cereda S, Galli L: PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) for patients with advanced pancreatic cancer: the ghost regimen. Cancer Lett; 2007 Oct 18;256(1):25-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Results of other recent trials comparing gemcitabine-erlotinib, gemcitabine-capecitabine and gemcitabine-oxaliplatin combinations to single agent gemcitabine are briefly commented from a clinical perspective.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17561341.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 23
  •  go-up   go-down


6. Shimizu M, Suzui M, Moriwaki H, Mori H, Yoshimi N: No involvement of beta-catenin gene mutation in gastric carcinomas induced by N-methyl-N-nitrosourea in male F344 rats. Cancer Lett; 2003 Jun 10;195(2):147-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The agent N-methyl-N-nitrosourea (MNU) is a direct acting carcinogen and induces well-differentiated adenocarcinoma on the rat gastric mucosa.
  • These results suggest that mutations in the beta-catenin gene are less contributory to the development of rat gastric carcinomas induced by MNU.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma, Papillary / genetics. Cytoskeletal Proteins / genetics. Membrane Proteins / genetics. Methylnitrosourea. Stomach Neoplasms / genetics. Trans-Activators / genetics
  • [MeSH-minor] Animals. Carcinogens. Cell Membrane / chemistry. Cell Nucleus / chemistry. Codon. Cytoplasm / chemistry. DNA Mutational Analysis. DNA, Neoplasm / genetics. Male. Phosphorylation. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. Rats. Rats, Inbred F344. beta Catenin

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. N-NITROSO-N-METHYLUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12767522.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Codon; 0 / Ctnnb1 protein, rat; 0 / Cytoskeletal Proteins; 0 / DNA, Neoplasm; 0 / Membrane Proteins; 0 / Trans-Activators; 0 / beta Catenin; 684-93-5 / Methylnitrosourea
  •  go-up   go-down


7. Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L, Staudacher C, Villa E, Di Carlo V: Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol; 2005 Jun;6(6):369-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Patients with advanced pancreatic adenocarcinoma have a poor response, progression-free survival, and overall survival with standard treatment.
  • We aimed to assess whether a four-drug regimen could improve 4 month progression-free survival compared with gemcitabine alone.
  • INTERPRETATION: The PEFG regimen could be considered for treatment of advanced pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intravenous. Italy. Male. Middle Aged. Palliative Care. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2005 Jun;6(6):352-3 [15948320.001]
  • (PMID = 15925814.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


8. Mook OR, Van Marle J, Vreeling-Sindelárová H, Jonges R, Frederiks WM, Van Noorden CJ: Visualization of early events in tumor formation of eGFP-transfected rat colon cancer cells in liver. Hepatology; 2003 Aug;38(2):295-304
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Visualization of early events in tumor formation of eGFP-transfected rat colon cancer cells in liver.
  • To determine cellular backgrounds of this preference, we generated an enhanced green fluorescent protein (eGFP)-expressing rat adenocarcinoma cell line (CC531s) that forms metastases in rat liver after administration to the portal vein.
  • Intravital videomicroscopy (IVVM) was used to visualize early events in the development of tumors in livers of live animals from the time of injection of the cancer cells up to 4 days afterward.
  • [MeSH-minor] Animals. Green Fluorescent Proteins. In Vitro Techniques. Indicators and Reagents / metabolism. Luminescent Proteins / genetics. Male. Microscopy, Electron. Neoplasm Transplantation. Portal Vein. Rats. Rats, Inbred Strains. Transfection. Tumor Cells, Cultured / transplantation. Tumor Cells, Cultured / ultrastructure

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hepatology. 2003 Nov;38(5):1314; author reply 1315 [14578875.001]
  • (PMID = 12883473.001).
  • [ISSN] 0270-9139
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indicators and Reagents; 0 / Luminescent Proteins; 147336-22-9 / Green Fluorescent Proteins
  •  go-up   go-down


9. Chu QD, Sun L, Li J, Byrnes K, Chervenak D, DeBenedetti A, Mathis JM, Li BD: Rat adenocarcinoma cell line infected with an adenovirus carrying a novel herpes-simplex virus-thymidine kinase suicide gene construct dies by apoptosis upon treatment with ganciclovir. J Surg Res; 2007 Nov;143(1):189-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rat adenocarcinoma cell line infected with an adenovirus carrying a novel herpes-simplex virus-thymidine kinase suicide gene construct dies by apoptosis upon treatment with ganciclovir.
  • In this study, we investigated the in vitro activity of this suicide gene therapy against the rat Mat BIII breast adenocarcinoma cell line, and assessed whether apoptosis was the responsible mechanism of cell killing.
  • CONCLUSION: Suicide gene therapy targeting the overexpression of eIF4E induces apoptosis and cell death in rat Mat BIII mammary adenocarcinoma cells.
  • [MeSH-major] Adenocarcinoma / therapy. Apoptosis / drug effects. Eukaryotic Initiation Factor-4E / metabolism. Ganciclovir / pharmacology. Genes, Transgenic, Suicide. Mammary Neoplasms, Animal / therapy
  • [MeSH-minor] Animals. Antiviral Agents / pharmacology. Antiviral Agents / therapeutic use. Cell Line, Tumor. Fluorescein-5-isothiocyanate. Fluorescent Dyes. Genetic Therapy / methods. Herpes Simplex / drug therapy. Rats. Simplexvirus / drug effects. Simplexvirus / enzymology. Simplexvirus / genetics. Thymidine Kinase / genetics. Thymidine Kinase / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GANCICLOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17950092.001).
  • [ISSN] 0022-4804
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Eukaryotic Initiation Factor-4E; 0 / Fluorescent Dyes; EC 2.7.1.21 / Thymidine Kinase; I223NX31W9 / Fluorescein-5-isothiocyanate; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


10. Cereda S, Rognone A, Mazza E, Fugazza C, Ceraulo D, Villa E, Reni M: Weekly epirubicin as salvage therapy in patients with gemcitabine-resistant advanced pancreatic cancer. J Chemother; 2009 Dec;21(6):698-700
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antibiotics, Antineoplastic / therapeutic use. Epirubicin / therapeutic use. Pancreatic Neoplasms / drug therapy. Salvage Therapy / methods
  • [MeSH-minor] Aged. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20071296.001).
  • [ISSN] 1973-9478
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


11. Seeni A, Takahashi S, Takeshita K, Tang M, Sugiura S, Sato SY, Shirai T: Suppression of prostate cancer growth by resveratrol in the transgenic rat for adenocarcinoma of prostate (TRAP) model. Asian Pac J Cancer Prev; 2008 Jan-Mar;9(1):7-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppression of prostate cancer growth by resveratrol in the transgenic rat for adenocarcinoma of prostate (TRAP) model.
  • Since it was recently proposed as a potential prostate cancer chemopreventive agent, we here performed an in vivo experiment to explore its effect in the Transgenic Rat for Adenocarcinoma of Prostate (TRAP) model, featuring the rat probasin promoter/SV 40 T antigen.
  • [MeSH-major] Adenocarcinoma / drug therapy. Anticarcinogenic Agents / therapeutic use. Disease Models, Animal. Prostatic Neoplasms / drug therapy. Stilbenes / therapeutic use
  • [MeSH-minor] Androgen Receptor Antagonists. Angiogenesis Inhibitors / therapeutic use. Animals. Apoptosis / drug effects. Blotting, Western. Body Weight / drug effects. COS Cells. Cercopithecus aethiops. Estradiol / blood. Gene Expression Regulation, Neoplastic / drug effects. Heterozygote. Humans. Male. Mice. Mice, Nude. Protein Biosynthesis. RNA, Messenger. Rats. Rats, Transgenic. Receptors, Androgen / genetics. Receptors, Androgen / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Serine Endopeptidases / genetics. Serine Endopeptidases / metabolism. Testosterone / blood. Ubiquitin / metabolism

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. RESVERATROL .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18439064.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / AR protein, human; 0 / Androgen Receptor Antagonists; 0 / Angiogenesis Inhibitors; 0 / Anticarcinogenic Agents; 0 / RNA, Messenger; 0 / Receptors, Androgen; 0 / Stilbenes; 0 / Ubiquitin; 0 / trypsin-like serine protease; 3XMK78S47O / Testosterone; 4TI98Z838E / Estradiol; EC 3.4.21.- / Serine Endopeptidases; Q369O8926L / resveratrol
  •  go-up   go-down


12. Takahashi S, Takeshita K, Seeni A, Sugiura S, Tang M, Sato SY, Kuriyama H, Nakadate M, Abe K, Maeno Y, Nagao M, Shirai T: Suppression of prostate cancer in a transgenic rat model via gamma-tocopherol activation of caspase signaling. Prostate; 2009 May 1;69(6):644-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppression of prostate cancer in a transgenic rat model via gamma-tocopherol activation of caspase signaling.
  • The purpose of the present study was to confirm effects of gamma-tocopherol on prostate cancer in the transgenic rat for adenocarcinoma of prostate (TRAP) model established in our laboratory.
  • However, quantitative evaluation of prostatic lesions demonstrated significantly suppression of sequential progression from PIN to adenocarcinoma in a dose-dependent manner, along with clear activation of caspases 3 and 7 in the ventral lobe in both experiments.
  • CONCLUSIONS: The present study clearly demonstrated that gamma-tocopherol suppresses prostate tumor progression in an in vivo TRAP model, and could be a candidate chemopreventive agent for human prostate cancer.
  • [MeSH-major] Adenocarcinoma / prevention & control. Prostatic Neoplasms / prevention & control. gamma-Tocopherol / therapeutic use
  • [MeSH-minor] Acid Phosphatase / genetics. Animals. Animals, Genetically Modified. Antioxidants / therapeutic use. Ceramides / metabolism. Chromatography, High Pressure Liquid. Humans. Isoenzymes / genetics. Male. Mice. Rats. Tocopherols / blood

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19143023.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Ceramides; 0 / Isoenzymes; 1406-66-2 / Tocopherols; 8EF1Z1238F / gamma-Tocopherol; EC 3.1.3.- / tartrate-resistant acid phosphatase; EC 3.1.3.2 / Acid Phosphatase
  •  go-up   go-down


13. Park JO, Lopez CA, Gupta VK, Brown CK, Mauceri HJ, Darga TE, Manan A, Hellman S, Posner MC, Kufe DW, Weichselbaum RR: Transcriptional control of viral gene therapy by cisplatin. J Clin Invest; 2002 Aug;110(3):403-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ad.Egr.TNF.11D, a replication-deficient adenoviral vector containing CArG elements cloned upstream of the cDNA for human recombinant TNF-alpha was used to treat human esophageal adenocarcinoma and rat colon adenocarcinoma cells in culture and as xenografts in athymic nude mice.
  • Cisplatin, a commonly used chemotherapeutic agent, causes tumor cell death by producing DNA damage and generating ROIs.
  • These studies also demonstrate an enhanced antitumor response without an increase in toxicity following treatment with Ad.Egr.TNF.11D and cisplatin, compared with either agent alone.
  • Chemo-inducible cancer gene therapy thus provides a means to control transgene expression while enhancing the effectiveness of commonly used chemotherapeutic agents.
  • [MeSH-major] Cisplatin / pharmacology. Immediate-Early Proteins. Transcription, Genetic / drug effects. Tumor Necrosis Factor-alpha / genetics
  • [MeSH-minor] Adenocarcinoma / therapy. Adenoviridae / genetics. Adenoviridae / physiology. Animals. Colonic Neoplasms. DNA-Binding Proteins / genetics. Disease Models, Animal. Early Growth Response Protein 1. Esophageal Neoplasms / therapy. Female. Genetic Therapy. Genetic Vectors / genetics. Genetic Vectors / physiology. Humans. Mice. Mice, Nude. Neoplasm Transplantation. Promoter Regions, Genetic. Rats. Transcription Factors / genetics. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1988 Sep 7;80(13):1039-44 [3411618.001]
  • [Cites] J Exp Med. 1988 Mar 1;167(3):1067-85 [3351434.001]
  • [Cites] J Exp Med. 1990 Jun 1;171(6):2025-41 [1972179.001]
  • [Cites] Gynecol Oncol. 1990 Sep;38(3):333-9 [2227544.001]
  • [Cites] Am J Pathol. 1991 Feb;138(2):447-53 [1992769.001]
  • [Cites] FEBS Lett. 1991 Jul 22;285(2):199-212 [1649771.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2419-22 [8384722.001]
  • [Cites] Cell. 1993 Sep 10;74(5):845-53 [8397073.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):229-34 [8083118.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):264-73 [7799030.001]
  • [Cites] Science. 1995 Oct 20;270(5235):404-10 [7569994.001]
  • [Cites] Nat Med. 1995 Aug;1(8):786-91 [7585181.001]
  • [Cites] Gene Ther. 1996 Jun;3(6):542-8 [8789804.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11313-8 [8876132.001]
  • [Cites] J Natl Cancer Inst. 1996 Nov 20;88(22):1635-44 [8931607.001]
  • [Cites] Hum Gene Ther. 1997 May 20;8(8):985-1001 [9195221.001]
  • [Cites] Gene Ther. 1998 Mar;5(3):293-300 [9614548.001]
  • [Cites] Cancer Gene Ther. 1998 Nov-Dec;5(6):344-9 [9917088.001]
  • [Cites] Adv Exp Med Biol. 1998;451:365-74 [10026898.001]
  • [Cites] J Pharm Pharmacol. 1999 Jul;51(7):755-70 [10467949.001]
  • [Cites] J Neurooncol. 2001 Mar;52(1):23-36 [11451200.001]
  • [Cites] Hiroshima J Med Sci. 1999 Sep;48(3):79-89 [10598410.001]
  • [Cites] Am J Clin Oncol. 2000 Aug;23(4):371-5 [10955866.001]
  • [Cites] J Clin Invest. 2000 Sep;106(6):763-71 [10995787.001]
  • [Cites] J Am Coll Surg. 2000 Nov;191(5):519-30 [11085732.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Jan;296(1):1-6 [11123355.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6A):4087-96 [11131677.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):784-90 [11309322.001]
  • [Cites] Mutat Res. 2001 Jul 1;478(1-2):23-43 [11406167.001]
  • [Cites] Curr Pharm Biotechnol. 2001 Jun;2(2):119-30 [11480417.001]
  • [Cites] Semin Oncol. 2001 Aug;28(4):336-43 [11498828.001]
  • [Cites] J Virol. 2001 Dec;75(23):11284-91 [11689608.001]
  • [Cites] Adv Drug Deliv Rev. 2001 Dec 17;53(2):135-54 [11731024.001]
  • [Cites] Acta Oncol. 2001;40(6):735-8 [11765068.001]
  • [Cites] Int J Cancer. 2002 Feb 1;97(4):410-5 [11802200.001]
  • [Cites] Science. 1985 Nov 8;230(4726):630-2 [2413547.001]
  • [Cites] Cancer Res. 1988 Apr 15;48(8):2179-83 [3349488.001]
  • [Cites] J Clin Oncol. 1989 Oct;7(10):1545-53 [2506316.001]
  • (PMID = 12163460.001).
  • [ISSN] 0021-9738
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / EGR1 protein, human; 0 / Early Growth Response Protein 1; 0 / Egr1 protein, mouse; 0 / Egr1 protein, rat; 0 / Immediate-Early Proteins; 0 / Transcription Factors; 0 / Tumor Necrosis Factor-alpha; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC151093
  •  go-up   go-down


14. Reni M, Cereda S, Balzano G, Passoni P, Rognone A, Zerbi A, Nicoletti R, Mazza E, Arcidiacono PG, Di Carlo V, Villa E: Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol; 2009 Nov;64(6):1253-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma.
  • PURPOSE: The role and timing of chemotherapy and radiation for treating stage III pancreatic adenocarcinoma remains controversial.
  • METHODS: Treatment-naive patients with stage III non-resectable pancreatic adenocarcinoma were treated with PEFG/PEXG (cisplatin, epirubicin, 5-fluorouracil (F)/capecitabine (X), gemcitabine) or PDXG (docetaxel substituting epirubicin) regimen for 6 months followed by radiotherapy (50-60 Gy) with concurrent F or X or G.
  • CONCLUSION: Combination chemotherapy with four-drug regimens followed by chemoradiation was a feasible strategy showing relevant results in stage III pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Capecitabine. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cisplatin / therapeutic use. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Disease Progression. Disease-Free Survival. Drug Therapy, Combination. Epirubicin / administration & dosage. Epirubicin / adverse effects. Epirubicin / therapeutic use. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / analogs & derivatives. Fluorouracil / therapeutic use. Humans. Male. Middle Aged. Survival Analysis. Treatment Failure. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19381632.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


15. Krupka TM, Dremann D, Exner AA: Time and dose dependence of pluronic bioactivity in hyperthermia-induced tumor cell death. Exp Biol Med (Maywood); 2009 Jan;234(1):95-104
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pluronic block copolymers have been shown to sensitize cancer cells resulting in an increased activity of antineoplastic agents.
  • DHD/K12/TRb rat adenocarcinoma cells were exposed to low-grade hyperthermia at 43 degrees C with or without Pluronic P85 or Pluronic L61.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. POLOXALENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Apr 1;355(9210):1119-25 [10791373.001]
  • [Cites] J Control Release. 2008 Sep 10;130(2):98-106 [18534704.001]
  • [Cites] Radiology. 2000 Oct;217(1):119-26 [11012432.001]
  • [Cites] Int J Hyperthermia. 2001 Mar-Apr;17(2):97-105 [11252361.001]
  • [Cites] Eur J Ultrasound. 2001 Jun;13(2):129-47 [11369525.001]
  • [Cites] J Vasc Interv Radiol. 2001 Jul;12(7):823-33 [11435538.001]
  • [Cites] Radiology. 2001 Aug;220(2):420-7 [11477246.001]
  • [Cites] Radiology. 2001 Oct;221(1):159-66 [11568334.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Nov;299(2):483-93 [11602658.001]
  • [Cites] Br J Cancer. 2001 Dec 14;85(12):1987-97 [11747344.001]
  • [Cites] J Pharm Sci. 2002 Jan;91(1):157-70 [11782905.001]
  • [Cites] Front Radiat Ther Oncol. 2002;36:171-6 [11842749.001]
  • [Cites] Radiology. 2002 Mar;222(3):797-804 [11867804.001]
  • [Cites] Curr Probl Surg. 2002 May;39(5):449-571 [12019420.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Jul;43(1):33-56 [12098606.001]
  • [Cites] Lasers Surg Med. 2002;31(3):158-63 [12224088.001]
  • [Cites] J Urol. 2003 Jan;169(1):338-46 [12478186.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Feb;304(2):845-54 [12538842.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Apr;125(4):929-37 [12698158.001]
  • [Cites] Chemistry. 2003 Aug 18;9(16):3930-6 [12916119.001]
  • [Cites] J Control Release. 2003 Aug 28;91(1-2):75-83 [12932639.001]
  • [Cites] Pharm Res. 2003 Oct;20(10):1581-90 [14620511.001]
  • [Cites] Radiology. 2004 Feb;230(2):450-8 [14688400.001]
  • [Cites] J Vasc Interv Radiol. 2004 Mar;15(3):269-74 [15028812.001]
  • [Cites] Radiologe. 2004 Apr;44(4):301-9 [15042293.001]
  • [Cites] Annu Rev Biochem. 1986;55:1151-91 [2427013.001]
  • [Cites] New Biol. 1991 Nov;3(11):1106-20 [1777484.001]
  • [Cites] Bioconjug Chem. 1996 Mar-Apr;7(2):209-16 [8983343.001]
  • [Cites] Nihon Rinsho. 1996 Jul;54(7):1949-54 [8741693.001]
  • [Cites] Radiology. 1997 Jan;202(1):205-10 [8988212.001]
  • [Cites] J Vasc Interv Radiol. 1998 Jan-Feb;9(1 Pt 1):101-11 [9468403.001]
  • [Cites] Prostate. 1998 Feb 15;34(3):195-202 [9492848.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3513-8 [9520397.001]
  • [Cites] AJR Am J Roentgenol. 1998 Apr;170(4):1015-22 [9530052.001]
  • [Cites] Ann Surg. 1998 Apr;227(4):559-65 [9563546.001]
  • [Cites] Hum Cell. 1998 Sep;11(3):167-74 [10086278.001]
  • [Cites] FEBS Lett. 1999 Mar 5;446(1):194-8 [10100641.001]
  • [Cites] Radiology. 1999 Aug;212(2):459-66 [10429704.001]
  • [Cites] FEBS Lett. 1999 Aug 6;456(2):339-42 [10456335.001]
  • [Cites] Pharm Res. 1999 Sep;16(9):1373-9 [10496652.001]
  • [Cites] Biochemistry. 2005 Mar 15;44(10):4042-54 [15751981.001]
  • [Cites] J Control Release. 2005 Aug 18;106(1-2):188-97 [15951044.001]
  • [Cites] FEBS J. 2005 Dec;272(23):6077-86 [16302971.001]
  • [Cites] Invest Radiol. 2006 Apr;41(4):422-7 [16523026.001]
  • [Cites] Mol Ther. 2006 Apr;13(4):804-13 [16199206.001]
  • [Cites] Paediatr Anaesth. 2006 Aug;16(8):890-1 [16884475.001]
  • [Cites] Invest Radiol. 2006 Dec;41(12):890-7 [17099428.001]
  • [Cites] J Surg Res. 2007 May 15;139(2):176-81 [17336331.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Mar;5(3):339-44 [17439762.001]
  • [Cites] Exp Biol Med (Maywood). 2007 Jul;232(7):950-7 [17609512.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Aug;19(6):418-26 [17493790.001]
  • [Cites] Abdom Imaging. 2007 May-Jun;32(3):332-8 [16933116.001]
  • [Cites] J Mol Cell Cardiol. 2007 Nov;43(5):616-26 [17884089.001]
  • [Cites] Cell Biochem Funct. 2007 Nov-Dec;25(6):669-72 [16933368.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Dec;19(10):805-6 [17892927.001]
  • [Cites] Radiology. 2008 Mar;246(3):796-803 [18309015.001]
  • [Cites] J Colloid Interface Sci. 2008 Jun 1;322(1):263-73 [18377918.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2452-63 [10861420.001]
  • (PMID = 18997100.001).
  • [ISSN] 1535-3702
  • [Journal-full-title] Experimental biology and medicine (Maywood, N.J.)
  • [ISO-abbreviation] Exp. Biol. Med. (Maywood)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA136857; United States / NCI NIH HHS / CA / R01 CA136857-01; United States / NCI NIH HHS / CA / R01CA1118399
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / pluronic L61; 106392-12-5 / Poloxamer; 8L70Q75FXE / Adenosine Triphosphate; 9003-11-6 / Poloxalene
  • [Other-IDs] NLM/ NIHMS359379; NLM/ PMC3293626
  •  go-up   go-down


16. Cuccia DJ, Bevilacqua F, Durkin AJ, Merritt S, Tromberg BJ, Gulsen G, Yu H, Wang J, Nalcioglu O: In vivo quantification of optical contrast agent dynamics in rat tumors by use of diffuse optical spectroscopy with magnetic resonance imaging coregistration. Appl Opt; 2003 Jun 1;42(16):2940-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo quantification of optical contrast agent dynamics in rat tumors by use of diffuse optical spectroscopy with magnetic resonance imaging coregistration.
  • We present a study of the dynamics of optical contrast agents indocyanine green (ICG) and methylene blue (MB) in an adenocarcinoma rat tumor model.
  • The absolute concentrations of contrast agent, oxyhemoglobin, deoxyhemoglobin, and water are measured simultaneously each second for approximately 10 min.
  • ICG, because of its binding to plasma proteins, behaves as a macromolecular contrast agent with a low vascular permeability.
  • In contrast, MB behaves as a small-molecular-weight contrast agent that leaks rapidly from the vasculature into the extravascular, extracellular space, and is sensitive to blood flow and the arterial input function.
  • [MeSH-major] Adenocarcinoma / diagnosis. Coloring Agents. Contrast Media. Indocyanine Green. Magnetic Resonance Imaging. Methylene Blue. Optics and Photonics. Skin Neoplasms / diagnosis
  • [MeSH-minor] Animals. Neoplasm Transplantation. Rats. Rats, Inbred F344

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. INDOCYANINE GREEN .
  • Hazardous Substances Data Bank. METHYLENE BLUE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12790443.001).
  • [ISSN] 0003-6935
  • [Journal-full-title] Applied optics
  • [ISO-abbreviation] Appl Opt
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P20-CA86182; United States / NCRR NIH HHS / RR / RR01192
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / Contrast Media; IX6J1063HV / Indocyanine Green; T42P99266K / Methylene Blue
  •  go-up   go-down


17. Reni M, Pasetto L, Aprile G, Cordio S, Bonetto E, Dell'Oro S, Passoni P, Piemonti L, Fugazza C, Luppi G, Milandri C, Nicoletti R, Zerbi A, Balzano G, Di Carlo V, Brandes AA: Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br J Cancer; 2006 Mar 27;94(6):785-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients >18 years, PS >or=50, with metastatic pancreatic adenocarcinoma previously treated with gemcitabine-containing chemotherapy, and progression-free survival (PFS) <12 months received a combination of raltitrexed (3 mg m(-2)) and oxaliplatin (130 mg m(-2)) every 3 weeks until progression, toxicity, or a maximum of six cycles.
  • Dose intensity for both drugs was 92% of the intended dose.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Deoxycytidine / analogs & derivatives. Deoxycytidine / pharmacology. Disease Progression. Drug Resistance, Neoplasm. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Metastasis. Organoplatinum Compounds / administration & dosage. Quality of Life. Quinazolines / administration & dosage. Salvage Therapy. Survival Analysis. Thiophenes / administration & dosage

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 1995 Jun;31A(6):882-7 [7646915.001]
  • [Cites] Cancer Invest. 1990;8(2):147-59 [2400936.001]
  • [Cites] Ann Oncol. 1996 Aug;7(6):593-600 [8879373.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):139-44 [9440735.001]
  • [Cites] Ann Oncol. 1998 Oct;9(10):1053-71 [9834817.001]
  • [Cites] Acta Oncol. 1998;37(7-8):651-9 [10050982.001]
  • [Cites] Int J Oncol. 1999 May;14(5):821-31 [10200331.001]
  • [Cites] Virchows Arch. 2004 Sep;445(3):236-47 [15258755.001]
  • [Cites] Oncology. 2004;67(2):93-7 [15539911.001]
  • [Cites] Cancer Invest. 2004;22(5):688-96 [15581049.001]
  • [Cites] Lancet Oncol. 2005 Jun;6(6):369-76 [15925814.001]
  • [Cites] Eur J Cancer. 1999 Jun;35(6):939-41 [10533475.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(11):2293-300 [10829050.001]
  • [Cites] Anticancer Res. 2000 Sep-Oct;20(5A):3259-64 [11062751.001]
  • [Cites] Anticancer Drugs. 2000 Sep;11(8):635-8 [11081455.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3447-55 [11481349.001]
  • [Cites] Oncologist. 2001;6(6):488-95 [11743211.001]
  • [Cites] Ann Oncol. 2002 May;13(5):716-20 [12075739.001]
  • [Cites] Br J Cancer. 2002 Jul 15;87(2):161-7 [12107836.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3270-5 [12149301.001]
  • [Cites] Ann Oncol. 2002 Jul;13(7):1072-9 [12176786.001]
  • [Cites] Br J Cancer. 2003 Apr 22;88(8):1180-4 [12698181.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3296-302 [12947065.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1430-8 [15084616.001]
  • [Cites] Cancer. 2004 Jul 1;101(1):133-8 [15221998.001]
  • [Cites] J Clin Oncol. 2004 Sep 15;22(18):3776-83 [15365074.001]
  • [Cites] Invest New Drugs. 1996;13(4):355-8 [8824356.001]
  • (PMID = 16508631.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Quinazolines; 0 / Thiophenes; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; FCB9EGG971 / raltitrexed
  • [Other-IDs] NLM/ PMC2361378
  •  go-up   go-down


18. Haack K, Linnebacher M, Eisold S, Zöller M, von Knebel Doeberitz M, Gebert J: Induction of protective immunity against syngeneic rat cancer cells by expression of the cytosine deaminase suicide gene. Cancer Gene Ther; 2000 Oct;7(10):1357-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of protective immunity against syngeneic rat cancer cells by expression of the cytosine deaminase suicide gene.
  • Using a stable CD transfectant of the tumorigenic rat adenocarcinoma cell line AS (AS/CD), an antitumoral response against the CD expressing cell line as well as the parental cell line could be induced by stepwise vaccinations in syngeneic animals.
  • AS/CD tumor regression occurred independently of 5-fluorocytosine treatment and was sufficient to protect 37% of the animals against subsequent challenge with tumorigenic doses of the parental AS cell line.
  • [MeSH-major] Adenocarcinoma / prevention & control. Genetic Therapy / methods. Immunization / methods. Nucleoside Deaminases / genetics. Pancreatic Neoplasms / prevention & control
  • [MeSH-minor] Adjuvants, Immunologic. Animals. Antigens, CD4 / immunology. Antigens, CD8 / immunology. Chromium / chemistry. Cytosine Deaminase. Female. Flow Cytometry. Gene Expression. Genetic Vectors. Horseradish Peroxidase / metabolism. Immunity, Cellular. Immunoenzyme Techniques. Injections, Intraperitoneal. Injections, Subcutaneous. Neoplasm Transplantation. Rats. Sensitivity and Specificity. T-Lymphocytes, Cytotoxic / drug effects. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Immunization.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CHROMIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11059694.001).
  • [ISSN] 0929-1903
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antigens, CD4; 0 / Antigens, CD8; 0R0008Q3JB / Chromium; EC 1.11.1.- / Horseradish Peroxidase; EC 3.5.4.- / Nucleoside Deaminases; EC 3.5.4.1 / Cytosine Deaminase
  •  go-up   go-down


19. Reni M, Cereda S, Mazza E, Passoni P, Nicoletti R, Balzano G, Zerbi A, Arcidiacono PG, Staudacher C, Di Carlo V: PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy. Am J Clin Oncol; 2008 Apr;31(2):145-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The activity and safety of this combination regimen were assessed by means of an observational study in a population of patients with progressive or recurrent pancreatic adenocarcinoma after gemcitabine-containing chemotherapy.
  • Prior treatment consisted of single agent gemcitabine (N = 17), gemcitabine-based chemotherapy (N = 4), or PEFG regimen (N = 25).
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Cisplatin / adverse effects. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Drug-Related Side Effects and Adverse Reactions. Epirubicin / administration & dosage. Epirubicin / adverse effects. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Male. Middle Aged. Survival Analysis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18391598.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


20. Cereda S, Reni M: Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer. J Chemother; 2008 Aug;20(4):509-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Between November 2004 and November 2005, 10 patients (median age 59; median KPS 80) with metastatic pancreatic adenocarcinoma, progressive disease after gemcitabine-containing chemotherapy, KPS >50, adequate organ function, were treated with weekly docetaxel at 30 mg/m-(2) until progressive disease.
  • Weekly administration of single-agent docetaxel does not seem to have any activity in the treatment of gemcitabine-resistant metastatic pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy. Salvage Therapy. Taxoids / therapeutic use
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Drug Administration Schedule. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged


21. Bonde P, Sui G, Dhara S, Wang J, Broor A, Kim IF, Wiley JE, Marti G, Duncan M, Jaffee E, Montgomery E, Maitra A, Harmon JW: Cytogenetic characterization and gene expression profiling in the rat reflux-induced esophageal tumor model. J Thorac Cardiovasc Surg; 2007 Mar;133(3):763-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic characterization and gene expression profiling in the rat reflux-induced esophageal tumor model.
  • OBJECTIVES: The reasons for the increasing incidence of esophageal adenocarcinoma are not clear.
  • A causal relation between gastroesophageal reflux disease and esophageal adenocarcinoma has been suggested.
  • Support for this comes from the development of esophageal adenocarcinoma in the rat reflux model.
  • The experiment was terminated at 9 months, and rat esophagi were harvested for histopathologic documentation of reflux-associated changes and evidence of tumor formation.
  • The rodent reflux model should be a valuable model for studying therapy and chemoprevention efforts for Barrett esophagus, whereas the established cell lines provide a useful resource for drug discovery and other high-throughput studies.
  • [MeSH-major] Adenocarcinoma / genetics. Cell Transformation, Neoplastic / pathology. Esophageal Neoplasms / genetics. Gastroesophageal Reflux / genetics
  • [MeSH-minor] Animals. Cell Line, Tumor. Cytogenetic Analysis. DNA, Complementary / analysis. Disease Models, Animal. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. In Vitro Techniques. Male. Mice. Mice, Nude. Neoplasms, Experimental. Rats. Rats, Sprague-Dawley. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - GERD.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17320581.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Grant] United States / FIC NIH HHS / TW / D43 TW06176
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Complementary
  •  go-up   go-down


22. Reni M, Cereda S, Bonetto E, Viganò MG, Passoni P, Zerbi A, Balzano G, Nicoletti R, Staudacher C, Di Carlo V: Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma: a dose-finding study. Cancer Invest; 2007;25(7):594-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma: a dose-finding study.
  • The aim of this study was to assess the maximum tolerated dose (MTD) of an intensified PEFG regimen administered every 14 days to patients with Stage III or metastatic pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Administration Schedule. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Male. Maximum Tolerated Dose. Middle Aged

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17852117.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


23. Clavijo J, Gomez-de-Segura IA, Gomez-García L, Vallejo-Cremades MT, Sanchez M, de Miguel E: Growth hormone protects the intestines but not the tumour from 5-fluorouracil toxicity in the short term in the rat. Eur J Gastroenterol Hepatol; 2004 Jan;16(1):75-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth hormone protects the intestines but not the tumour from 5-fluorouracil toxicity in the short term in the rat.
  • The aim of this study was to determine whether exogenously administered growth hormone modified the effect of 5-fluorouracil on the gut and an implanted colon adenocarcinoma in the rat METHODS: An adenocarcinoma was implanted into rats that had been treated with 5-fluorouracil and growth hormone 3 days previously.
  • CONCLUSIONS: Growth hormone protects the intestines from the deleterious effects of 5-fluorouracil while preserving its antitumoural action on the adenocarcinoma in the short term.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / adverse effects. Colonic Neoplasms / drug therapy. Fluorouracil / adverse effects. Growth Hormone / therapeutic use. Intestines / drug effects
  • [MeSH-minor] Animals. Apoptosis / drug effects. Bacterial Translocation / drug effects. Body Weight. Cell Line, Tumor. Male. Rats. Rats, Inbred Strains. Receptors, Somatotropin / analysis. Tumor Suppressor Protein p53 / analysis

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15095856.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Receptors, Somatotropin; 0 / Tumor Suppressor Protein p53; 9002-72-6 / Growth Hormone; U3P01618RT / Fluorouracil
  •  go-up   go-down


24. Cadieux PA, Mikolajczak SA, Reeves J, Strathdee C, Reid G, Panchal CJ, Clarke MW: Rat PSP94 inhibits the growth and viability of the rat adenocarcinoma cell line PAIII in vitro. Cancer Invest; 2006 Apr-May;24(3):246-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rat PSP94 inhibits the growth and viability of the rat adenocarcinoma cell line PAIII in vitro.
  • To further validate this potential and investigate the protein within a homologous setting, we examined the effects of rat PSP94 on the growth of the rat prostate adenocarcinoma cell line PAIII in vitro.
  • To generate rat PSP94, we used both a plasmid-based expression system and a recombinant rat PSP molecule.
  • Rat PSP was shown to inhibit the growth and survival of PAIII cells in a dose-dependent manner with > 90 percent reductions in both observed.
  • [MeSH-major] Adenocarcinoma / drug therapy. Cell Proliferation / drug effects. Prostatic Neoplasms / drug therapy. Prostatic Secretory Proteins / pharmacology
  • [MeSH-minor] Animals. Apoptosis / drug effects. Blotting, Northern. Blotting, Western. Cell Line, Tumor. Cell Survival / drug effects. Cloning, Molecular. Dose-Response Relationship, Drug. Electrophoresis, Polyacrylamide Gel. In Situ Nick-End Labeling. In Vitro Techniques. Male. Rats. Recombinant Proteins. Reverse Transcriptase Polymerase Chain Reaction. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Transfection

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16809150.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Prostatic Secretory Proteins; 0 / Recombinant Proteins; 0 / beta-microseminoprotein
  •  go-up   go-down


25. Reni M, Passoni P, Panucci MG, Nicoletti R, Galli L, Balzano G, Zerbi A, Di Carlo V, Villa E: Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. J Clin Oncol; 2001 May 15;19(10):2679-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma.
  • PURPOSE: To evaluate the efficacy and toxicity of a cisplatin, epirubicin, gemcitabine, and fluorouracil (PEF-G) schedule on stage IV pancreatic adenocarcinoma.
  • PATIENTS AND METHODS: Patients < or = 70 years, with no prior chemotherapy and with bidimensionally measurable stage IV pancreatic adenocarcinoma, Eastern Cooperative Oncology Group performance status < or = 2, and adequate bone marrow, kidney, and liver function were eligible for this trial.
  • Eligibility criteria for clinical benefit assessment were pain with at least a daily analgesic consumption of two nonsteroidal anti-inflammatory drugs or Karnofsky performance status between 50 and 70.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Administration Schedule. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Metastasis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11352960.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


26. Dass CR, Burton MA: Modified microplex vector enhances transfection of cells in culture while maintaining tumour-selective gene delivery in-vivo. J Pharm Pharmacol; 2003 Jan;55(1):19-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A non-commercial liposome (dimethyl dioctadecyl ammonium bromide:dioleoyl phosphatidylethanolamine) was compared with a commercial variety (Lipofectamine) for transfection of cultured rat adenocarcinoma cells and in an in-vivo kidney tumour model.
  • [MeSH-major] Cation Exchange Resins / chemistry. Drug Carriers / chemistry. Genetic Therapy / methods. Indicators and Reagents / chemistry. Lipids / chemistry. Transfection

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12625863.001).
  • [ISSN] 0022-3573
  • [Journal-full-title] The Journal of pharmacy and pharmacology
  • [ISO-abbreviation] J. Pharm. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cation Exchange Resins; 0 / Cations; 0 / Drug Carriers; 0 / Indicators and Reagents; 0 / Lipids; 0 / Lipofectamine; 0 / Liposomes
  •  go-up   go-down


27. Reni M, Sartori N, Mambrini A, Berardi R, Passardi A, Milella M, Cereda S, Tronconi MC, Aprile G, Cordio S, Pasetto LM, Rognone A, Pederzoli P, Falconi M: An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change? Anticancer Drugs; 2010 Apr;21(4):459-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change?
  • A series of 650 patients treated between 1997 and 2007 at 10 Italian centers was analyzed to assess treatment trends and efficacy in stage III pancreatic adenocarcinoma.
  • The inclusion criteria were pathological diagnosis of stage III pancreatic adenocarcinoma; age more than 18 years, Eastern Cooperative Oncology Group performance status less than 3, and no past therapy.
  • Most patients (95%) received up-front chemotherapy, which mainly consisted of gemcitabine alone (N=323), gemcitabine-based four-drug combinations (N=107), gemcitabine-platinum compound doublets (N=87), or intra-arterial gemcitabine-free triplets (N=57).
  • The median and 1-year OS were 9.5 months and 35.5% for patients treated with gemcitabine; 8.9 months and 36.8% for those treated with gemcitabine-free intra-arterial triplets; 13.3 months and 55.8% for those treated with gemcitabine-platinating agent doublets; and 16.2 months and 62.6% for those treated with gemcitabine-based four-drug combinations.
  • The use of a strategy consisting of a gemcitabine-platinating agent containing chemotherapy followed by consolidation chemoradiation has been increasing over time and may represent a suitable choice in the therapeutic management of stage III pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Drug Therapy / trends. Humans. Italy / epidemiology. Middle Aged. Neoplasm Staging. Survival Analysis. Treatment Outcome






Advertisement